Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06976177 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 16, 2025 (before its estimated August 19, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013 after treatment.The treatment duration for Part A MAD study is 52 weeks and the duration for Part B study is 26 weeks.
Trial Details
NCT Number NCT06976177
Lead Sponsor Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Conditions
(from sponsor)		 Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Related terms Hyperparathyroidism, Secondary
Enrollment 310 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov